Browsing by Author "Liang, Weida"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Discovery and Biological Characterization of PRMT5:MEP50 Protein-Protein Interaction Inhibitors
    (American Chemical Society, 2022) Asberry, Andrew M.; Cai, Xinpei; Deng, Xuehong; Liu, Sheng; Santiago, Ulises; Sims, Hunter; Liang, Weida; Xu, Xueyong; Wan, Jun; Jiang, Wen; Camacho, Carlos; Dai, Mingji; Hu, Chang-Deng; Medical and Molecular Genetics, School of Medicine
    Protein arginine methyltransferase 5 (PRMT5) is a master epigenetic regulator and an extensively validated therapeutic target in multiple cancers. Notably, PRMT5 is the only PRMT that requires an obligate cofactor, methylosome protein 50 (MEP50), to function. We developed compound 17, a novel small molecule PRMT5:MEP50 protein:protein interaction (PPI) inhibitor, after initial virtual screen hit identification and analog refinement. Molecular docking indicated that compound 17 targets PRMT5:MEP50 PPI by displacing MEP50 W54 burial into a hydrophobic pocket of PRMT5 TIM barrel. In vitro analysis indicates IC50 <500 nM for prostate and lung cancer cells with selective, specific inhibition of PRMT5:MEP50 substrate methylation and target gene expression, and RNA-seq analysis suggests that compound 17 may dysregulate TGF-β signaling. Compound 17 provides a proof of concept in targeting PRMT5:MEP50 PPI, as opposed to catalytic targeting, as a novel mechanism of action and supports further preclinical development of inhibitors in this class.